z-logo
Premium
Anti‐inflammatory activity of creatine supplementation in endothelial cells in vitro
Author(s) -
Nomura Akihiro,
Zhang Minjie,
Sakamoto Tohru,
Ishii Yukio,
Morishima Yuko,
Mochizuki Mie,
Kimura Toru,
Uchida Yoshiyuki,
Sekizawa Kiyohisa
Publication year - 2003
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0705316
Subject(s) - medicine , endocrinology , intracellular , endothelial stem cell , creatine , endothelial dysfunction , endothelium , biology , chemistry , in vitro , pharmacology , biochemistry
Creatine (CR) supplementation augments muscle strength in skeletal muscle cells by increasing intracellular energy pools. However, the effect of CR supplementation on endothelial cells remains to be clarified. In this study, we investigated whether CR supplementation had any anti‐inflammatory activity against human pulmonary endothelial cells in culture. We confirmed that supplementation with 0.5 m M CR significantly increased both intracellular CR and phosphocreatine (PC) through a CR transporter while keeping intracellular ATP levels constant independent of CR supplementation and a CR transporter antagonist. In the assay system of endothelial permeability, supplementation with 5 m M CR significantly suppressed the endothelial permeability induced by serotonin and H 2 O 2 . In cell adhesion experiments, supplementation with 5 m M CR significantly suppressed neutrophil adhesion to endothelial cells. In the measurement of adhesion molecules, CR supplementation with more than 0.5 m M CR significantly inhibited the expressions of ICAM‐1 and E‐selectin on endothelial cells, and the inhibition was significantly suppressed by an adenosine A 2A receptor antagonist. The present study suggests that CR supplementation has anti‐inflammatory activities against endothelial cells.British Journal of Pharmacology (2003) 139 , 715–720. doi: 10.1038/sj.bjp.0705316

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here